International Assets Investment Management LLC Makes New Investment in Boston Scientific Corporation $BSX

International Assets Investment Management LLC bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 17,351 shares of the medical equipment provider’s stock, valued at approximately $750,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd purchased a new stake in Boston Scientific in the first quarter valued at $28,000. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Boston Scientific in the 1st quarter valued at about $32,000. Measured Wealth Private Client Group LLC lifted its holdings in shares of Boston Scientific by 244.9% in the 1st quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 387 shares during the last quarter. Kelleher Financial Advisors acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at about $25,000. Finally, Nvwm LLC boosted its position in shares of Boston Scientific by 526.2% in the 3rd quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 542 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on BSX shares. Barclays decreased their price objective on Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating for the company in a report on Friday, October 30th. Oppenheimer cut shares of Boston Scientific from an “outperform” rating to a “market perform” rating in a report on Thursday, October 29th. Sanford C. Bernstein reduced their price target on shares of Boston Scientific from $54.00 to $49.00 and set an “outperform” rating for the company in a research report on Thursday, October 29th. Rothschild & Co Redburn decreased their price target on shares of Boston Scientific from $106.00 to $78.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Finally, Citigroup lowered their price objective on shares of Boston Scientific from $48.00 to $44.00 and set a “neutral” rating on the stock in a research report on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $61.43.

Boston Scientific Stock Up 1.5%

Boston Scientific stock opened at $44.67 on Wednesday. The stock’s 50 day moving average price is $44.19 and its 200 day moving average price is $55.23. Boston Scientific Corporation has a 1-year low of $39.57 and a 1-year high of $105.65. The company has a market cap of $64.74 billion, a PE ratio of 18.93, a price-to-earnings-growth ratio of 1.30 and a beta of 0.60. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.36 and a quick ratio of 0.81.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The company had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same period last year, the company posted $0.75 earnings per share. The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. On average, sell-side analysts predict that Boston Scientific Corporation will post 3.17 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.